Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.

Ana Victoria Ponce-Bobadilla,Sven Stodtmann,Mong-Jen Chen,Insa Winzenborg,Sven Mensing,Jonas Blaes,Tobias Haslberger,Loic Laplanche,Ingeborg Dreher,Nael M Mostafa

Clinical pharmacokinetics（2023）

引用 1|浏览9

暂无评分

摘要

The ELISA assay was found to be optimal for capturing impact of ADA on PK. The developed adalimumab popPK model is robust in predicting PK profiles for CD and UC patients whose PK was impacted by ADA.

查看译文

关键词

ulcerative colitis,population pharmacokinetic modeling,adalimumab,crohns

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要